Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review

Eva M Donato, Miguel Fernández-Zarzoso, Jose Antonio Hueso, Javier de la Rubia

1Hematology Service, University Hospital Doctor Peset, Valencia, Spain; 2Department of Internal Medicine, Universidad Católica de Valencia “San Vicente Mártir,” Valencia, Spain

Abstract: Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) account for ~10% and 2%–3% of all cases of lymphoid neoplasms, respectively. Up to 30% of patients with HL are refractory or relapse after first-line therapy, and elderly patients with HL represent a subgroup of patients with suboptimal responses to the currently available treatments. Five-year overall survival for ALCL patients is 50%–80% with conventional chemotherapy. Therefore, new therapeutic approaches are needed for these groups of patients. Brentuximab vedotin is a chimeric IgG1 anti-CD30 antibody–drug conjugate that has all the features that are necessary to make a substantive difference with the standard therapies in patients with HL and ALCL: a novel mechanism of action, single-agent activity, non-cross-resistance, and safety both in the relapsed-refractory and in the front-line setting. This review provides an update of the results of the most relevant clinical trials including brentuximab vedotin for patients with HL and ALCL conducted to date.

Keywords: anaplastic large-cell lymphoma, anti-CD30 antibody, brentuximab vedotin, Hodgkin lymphoma

Introduction

Hodgkin lymphoma (HL) most commonly affects young adults and accounts for ~10% of all cases of lymphoma in the United States and represents 5% of all annual deaths from lymphoma.1 Cutaneous and systemic anaplastic large-cell lymphomas (ALCL) are a subtype of peripheral T-cell lymphomas that account for 2%–8% of all lymphoid neoplasms.2,3 Primary systemic ALCL represents 2%–8% of non-Hodgkin lymphomas in adults and 20%–30% of large-cell lymphomas in children.3 ALK expression can be observed in up 85% of ALCL while the remaining cases are considered ALK-negative. Both subtypes show different features and are considered as 2 different entities in the updated World Health Organization classification.3

Currently available front-line therapies can cure most of the younger patients with HL, but up to 30% of them are refractory or relapse after first-line therapy. The standard of care for these patients is second-line chemotherapy followed by autologous stem cell transplantation (ASCT), and it is associated with a 50%–55% cure rate, but new treatments are need for relapsed and refractory HL (RRHL) patients after ASCT. Though HL predominantly affects young people, elderly patients represent a subgroup of patients who are the most challenging to treat and there are scarce options for those who fail first-line therapy. Therefore, improved outcomes with the introduction of agents with new mechanism are also clearly needed for these patients. Finally, 5-year
overall survival (OS) for ALK-positive patients is 70%–80% with conventional chemotherapy but it is only 50% for ALK-negative patients.4 Few effective treatments are available for relapsed or refractory ALK-negative patients, and novel therapeutic options are warranted to improve prognosis in this uncommon subtype of lymphoma.

CD30 is a 120-kd transmembrane cytokine receptor of the tumor necrosis factor receptor family4 that is expressed in the lymphoid cells of most patients with HL and ALCL. CD30 expression is confined to activated lymphocytes and eosinophils, usually on lymphoid tissues, but not on peripheral blood cells. CD30 has thus been identified as an attractive target for therapy. Brentuximab vedotin (BV) is a chimeric IgG1 anti-CD30 antibody–drug conjugated by a protease-cleavable linker to the microtubule-disrupting agent monomethyl auristatin E that has shown impressive antitumor activity in both HL and ALCL.5 Targeted delivery of monomethyl auristatin E to CD30 expressing tumor cells is the primary mechanism of action of BV. Additional mechanisms of tumor cell death that may contribute to the clinical activity of this drug include antibody-dependent cellular phagocytosis, immunogenic cell death, and the bystander effect. Availability of BV has become an important step forward in the improvement of the outcome of patients with relapsed and refractory HL.6 Furthermore, the significant clinical activity observed and the good tolerability of BV has allowed for widespread investigation and use of BV among a variety of lymphoma patients, and several groups are testing BV-based therapies in the management of newly diagnosed patients with HL and ALCL, with encouraging preliminary results.

In this review, the use of BV-based therapies for the treatment of relapsed/refractory HL and ALCL and the most common BV-associated side effects will be reviewed, with the addition of some perspectives of how this new drug would impact the clinical management of these patients in the future.

**Clinical efficacy of BV in HL**

**Relapsed/refractory HL**

**Approved indications**

In the pre-BV era, patients with RRHL after ASCT had few therapeutic options with median OS ranging from 10.5 to 27.6 months.7–8 This scenario, however, changed with the introduction of BV.

In a Phase II, single-arm study, testing the efficacy and safety of BV monotherapy, 102 patients with RRHL after ASCT were included. BV was administered at a dose of 1.8 mg/kg, once every 3 weeks, for up to 16 cycles.9 Overall response rate (ORR) was 75%, with a 34% complete response (CR) rate. Notably, 71% of patients in the trial had refractory disease at the time of transplant, highlighting the remarkable activity of single-agent BV in patients with advanced-stage disease who are refractory to current standard options, including high-dose therapy. This trial was the first to demonstrate substantial activity of BV in patients with advanced disease and limited treatment options and led to the accelerated approval of BV by the US Food and Drug Administration (2011) and the European Medicines Agency (2012) for the treatment of patients with HL who have relapsed after an ASCT or following 2 prior lines of therapy.

The long-term follow-up results of the pivotal trial showed a 5-year progression-free survival (PFS) of 22% and an OS of 41%. Patients who achieved CR (n=34) had PFS and OS rates of 52% (95% confidence interval [CI], 34–69) and 64% (95% CI, 48–80), respectively.10 In this trial, most patients in CR (28 out of the 34 patients) did not receive consolidation with allogeneic transplantation and the PFS and OS rates in these patients were 48% and 60%, respectively. Several reports have also addressed the efficacy of single-agent BV in RRHL patients treated outside conventional clinical trials. Overall, these studies show clinical outcomes similar to those reported by the pivotal trial, with CR rates ranging from 18% to 46% and with PFS ranging from 5.7 to 10.2 months.5

The Phase III randomized, double-blind, placebo-controlled AETHERA trial studied the role of consolidation treatment with BV to prevent relapse after ASCT.11 Patients included in the trial had at least 1 of the following risk factors: primary refractory HL, relapsed HL (initial remission duration of <12 months), or extranodal involvement at relapse. Patients were randomized to receive either BV (n=165) at a dose of 1.8 mg/kg on day 1 of every 21-day cycle for up to 16 cycles or placebo (n=165), starting 30–45 days after ASCT. The median PFS was 42.9 and 24.1 months for those patients receiving BV and placebo, respectively (HR =0.57, P=0.0013) with a 3-year PFS rate of 61% (95% CI, 52–68) for the BV group and 43% (95% CI, 36–51) for the placebo arm.12 There was significantly more neuropathy (56%) and neutropenia (35%) in the BV arm. No differences in OS were observed between both groups of patients, probably because most patients in the placebo arm received BV as rescue therapy at relapse. Pretransplant PET was not required in the trial, and therefore the potential benefit of the role of post-transplant maintenance with BV in patients with PET-confirmed CR remains unknown. However, the analysis of the subgroup of patients with PET-negative pre-ASCT did...
not show differences in terms of PFS when compared with patients receiving placebo.

**BV-based combinations**

It is generally accepted that in patients with HL, remission status pre-ASCT is highly predictive of outcome, and the incorporation of BV into a rescue therapy regimen before transplant could provide a unique opportunity to improve response. The current approved indications of BV do not include transplant-eligible patients refractory to second-line therapy, and several groups have tested the usefulness of BV either alone or in combination as pretransplant rescue therapy for this group of patients.

The role of second-line therapy before ASCT with BV monotherapy was analyzed by Chen et al in a series of 37 patients with RRHL. In this trial, patients received 4 doses of standard BV. The ORR was 68% and 18 patients (13 in CR) proceeded to ASCT without further combination chemotherapy. This trial showed that monotherapy with BV can be effective and safely administered in RRHL patients as a bridge to ASCT. Additional studies have reported results of the administration of BV either sequentially or in combination with several chemotherapy regimens as part of a salvage strategy prior to ASCT including gemcitabine-based, ifosfamide, carboplatin, and etoposide (ICE), bendamustine, or etoposide, methylprednisolone, cytarabine, and cisplatin (ESHAP) therapies, achieving PET-negativity prior to ASCT ranging from 70% to 76% (Table 1). Interestingly, and although studies cannot be directly compared, results show that patients in CR after single-agent BV or after BV-based combinations achieve similar results post-ASCT with PFS higher than 80% at 2 years.

Finally, early data indicate that the combination of BV with the immune checkpoint inhibitor nivolumab is an active and well-tolerated salvage combination in the RRHL setting with an ORR of 100% and CR rates ranging from 50 to 62.5%. A Phase III confirmatory study comparing nivolumab plus BV to BV alone for patients with RRHL following ASCT or who are transplant ineligible (CheckMate 812, NCT03138499) is currently ongoing. In addition, a randomized Phase III trial comparing pembrolizumab versus BV for RRHL patients after ASCT or those who are ASCT ineligible is also currently active (NCT02684292).

**Retreatment with BV**

A Phase II study investigated the safety and antitumor activity of retreatment with BV in patients who previously achieved CR or partial response (PR) with this drug. The reported ORR was 60% (30% CR) with a median duration of response for patients achieving PR or better of 9.2 months.

**BV in the front-line setting**

**Elderly patients**

Given the response rates observed with BV in RRHL patients and the high toxicity observed with standard front-line adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy in elderly patients, a reasonable option could be to test single-agent BV in elderly patients with newly diagnosed HL. The efficacy and safety of BV as front-line therapy was reported in a Phase II study including 27 HL patients over the age of 60 years. The ORR and CR were 92% and 73%, respectively. The median PFS was 10.5 months (range, 2.6–22.3) for all efficacy-eligible patients (n=26) and 11.8 months (range, 4.1–22.3) for those achieving CR. Similar results were confirmed by another study including 38 patients who were considered unfit for standard chemotherapy. The complete metabolic response rate following cycle 4 was 100%.

**Table 1** Results of the studies including BV sequentially or in combination with chemotherapy as part of a salvage strategy prior to SCT^a^

<table>
<thead>
<tr>
<th>Author</th>
<th>Number of patients</th>
<th>Objective response (%)</th>
<th>PET-negative prior to SCT (%)</th>
<th>SCT performed (%)</th>
<th>PFS</th>
<th>OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michallet et al^15</td>
<td>11</td>
<td>CR: 73</td>
<td>73</td>
<td>100</td>
<td>11.2 months (95% CI, NA)</td>
<td>1 year: 60% (95% CI, NA)</td>
</tr>
<tr>
<td>Moskowitz et al^14</td>
<td>45</td>
<td>CR: 76</td>
<td>76</td>
<td>98</td>
<td>2 years: 80% (95% CI, 68–92)</td>
<td>2 years: 95% (95% CI, 88–100)</td>
</tr>
<tr>
<td>Cassaday et al^17</td>
<td>16</td>
<td>CR: 88</td>
<td>NA</td>
<td>75</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>La Casse et al^18</td>
<td>55</td>
<td>CR: 74</td>
<td>74</td>
<td>73</td>
<td>1 year: 80% (95% CI, 60–90)</td>
<td>NA</td>
</tr>
<tr>
<td>Garcia-Sanz et al^19</td>
<td>66</td>
<td>CR: 70</td>
<td>70</td>
<td>92</td>
<td>1 year: 87% (95% CI, NA)</td>
<td>1 year: 90% (95% CI, NA)</td>
</tr>
</tbody>
</table>


| Abbreviations: BV, brentuximab vedotin; SCT, stem cell transplantation; PFS, progression-free survival; OS, overall survival; CI, confidence interval; NA, not available; CR, complete response; PR, partial response. | 4585

OncoTargets and Therapy 2018:11 submit your manuscript | www.dovepress.com
Dovepress
26%, with a median PFS was 7 months. Finally, 28 of the 31 evaluable patients had progressed at the time of the report.  

To improve these results, combinations of BV plus bendamustine or dacarbazine have been tested as front-line induction therapy in elderly patients with HL. The association of BV plus dacarbazine showed an ORR of 100% and a CR rate of 62%. With a median follow-up time of 21.6 months, median PFS was 17.9 months (not reached for patients in CR and 10.8 months for patients in PR). BV plus bendamustine has been associated with an ORR of 100% and a CR rate of 88% but with a much higher incidence of serious adverse events (AEs; 65% of patients). According to the available results, BV plus dacarbazine seems to be a better tolerated regimen and a more suitable front-line therapy for this subgroup of patients. Finally, the combination of BV and nivolumab is also being explored as first-line therapy in older patients in a Phase II study (NCT02758717), but no data are available yet.

Front-line treatment with BV

These results of BV in the relapsed and refractory setting prompted the launch of several trials focused on the role of BV as front-line therapy for patients with HL. A Phase I study evaluated the association of BV with ABVD in 25 patients with advanced-stage HL. Preliminary results showed an incidence of pulmonary toxicity of 44% including 2 deaths. A second cohort tested the combination of adriamycin, vinblastine, and dacarbazine (AVD) plus BV in an additional 26 patients showing that BV can be safely combined with AVD at full therapeutic doses with a CR rate of 96% and an estimated 5-year PFS and OS of 92% and 100%, respectively.

BV plus AVD combination has also been tested in 29 patients with early-stage classical HL with unfavorable risk features. Patients received 4 cycles of BV and AVD, and 25 of them also underwent site radiation therapy (30 Gy) after induction, with every patient achieving CR. With a median follow-up of 18.8 months, 1-year PFS was 93.3% (95% CI, 84–102). The role of the combination of AVD plus BV versus AVD in patients with newly diagnosed stage III or IV classic HL was examined in the large international prospective randomized ECHELON-1 trial. In this study, 664 patients received BV plus AVD and 670 received ABVD. At a median follow-up of 24.9 months, 2-year PFS in the BV plus AVD and ABVD groups were 82.1% (95% CI, 78.7–85) and 77.2% (95% CI, 73.7–80.4), respectively. BV plus AVD showed superior efficacy to ABVD in these patients, with a 4.9 percentage-point lower combined risk of progression, death, or non-CR, and use of subsequent anticancer therapy at 2 years.

In another Phase II trial, 104 newly diagnosed patients with HL were randomly allocated to receive 6 cycles of BV, etoposide, cyclophosphamide, doxorubicin, procarbazine, and prednisone (BEACOPP) or BV, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD). Results showed that both combinations produced a similar CR (86% for BrECAPP and 88% for BrECADD) and 1-year PFS (98% for BrECAPP and 94% for BrECADD) rates than conventional bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP). A randomized, Phase III trial is currently comparing the efficacy and safety of first-line BrECADD and BEACOPP in advanced-stage HL (HD21 trial, NCT02661503).

Clinical efficacy of BV in systemic ALCL

CD30 is expressed on the surface of cells in ALCL, a subtype of peripheral T-cell lymphomas, representing ~2%–3% of all lymphoid neoplasms. Cases of ALK-positive ALCL are associated with a characteristic translocation, t(2;5) (p23;q35), resulting in a fusion gene, NPM-ALK, encoding a protein with tyrosine kinase activity. CD30 and ALK are key molecules involved in the pathogenesis, diagnosis, and treatment of ALCL, and it has been clearly established that ALK-positive patients have fared better than ALK-negative patients due to their high sensitivity to anthracycline-based chemotherapy. Given this favorable outcome, cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) is considered the standard front-line therapy for ALK-positive ALCL.

Relapsed and refractory ALCL

About half of patients with systemic ALCL will relapse after front-line treatment. Most adults with relapsed and refractory ALCL (RRALCL) have poor outcomes and consolidation with ASCT seems to be the standard therapy. However, given the strong and uniform expression of CD30, the antibody–drug conjugate BV has been widely tested in the relapse and refractory setting. Initially, 45 patients with relapsed CD30-positive HL and systemic ALCL were included in a Phase I multicenter, dose-escalation study of BV monotherapy. Two out of the 45 patients with systemic ALCL achieved CR, 1 in the 1.2 mg cohort and 1 in the 2.7 mg cohort (the maximum tolerated dose was 1.8 mg/kg given every 3 weeks). Another multinational, open-label, Phase II study evaluated the safety and efficacy of BV as single agent in 58 patients with RRALCL. The median age
was 52 years (range, 14–76), and the median (range) of prior chemotherapy regimens was 2 (1–6). Half of the patients were in relapse at study entry and 50% were refractory to their most recent therapy. Most patients (72%) had ALK-negative ALCL. BV was administered at a dose of 1.8 mg/kg, once every 3 weeks for up to 16 cycles, and the ORR was 86%. Based on these findings, BV was approved by the US Food and Drug Administration in 2011 for the treatment of patients with RRALCL. The updated results of this clinical trial have been recently reported. With a 5-year follow-up, 38 (66%) patients achieved CR, and these objective responses were independent of ALK status or number of prior therapies. The estimated OS rate for the whole series was 79% and 25% for the subgroup of patients not achieving CR. In addition, PFS rate among CR patients was substantially higher than in total enrolled patients (57% versus 39%, respectively). BV therapy showed long-lasting CR both in the group of patients undergoing consolidation with ASCT and in those patients not receiving ASCT. Overall, 25 patients (43%) had died, 14 of them due to disease progression.

Similar results have been reported by an Italian observational, multicenter, retrospective study including 40 patients with systemic ALCL. All these patients received treatment with single-agent BV at the time of relapse with an ORR of 62.5% (45% CR and 17.5% PR). As in aggressive B-cell lymphoma, CHOP is considered the standard front-line therapy for patients with peripheral T-cell lymphomas. However, relapses are commonly observed, particularly in ALK-negative patients. To improve clinical results, front-line treatment combining BV with cyclophosphamide, doxorubicin, and prednisone (CHP) was evaluated in a Phase I clinical trial including 26 patients with CD30-positive peripheral T-cell lymphoma (19 with systemic ALCL). Patients received standard dose of BV with CHP on day 1 of each 21-day cycle. After 6 cycles, responding patients could receive up to 10 additional cycles of BV alone. With a median follow-up of 59.6 months, the objective response was 100% including 24 CR and 2 PR patients. The median PFS was 34.6 months and the estimated 5-year PFS was 47% for patients with ALCL. The median OS was not reached, and the estimated 5-year OS was 79%. Nine out of the 19 ALCL patients (3 ALK+, 6 ALK–) remained in remission after 5 years of follow-up. Given those promising results, a Phase III, randomized clinical trial comparing front-line BV + CHP to CHOP for peripheral T-cell lymphomas is currently ongoing (ECHELON-2 trial, NCT01777152).

Safety and BV-associated side effects

In the Phase II pivotal study previously done in patients with RRHL, the most common grade 3 or grade 4 AEs observed were peripheral neuropathy (PN) (8%), fatigue (2%), neutropenia (20%), and diarrhea (1%). The 56 patients who experienced PN symptoms were followed for improvement and/or resolution. After 3 years of follow-up, PN resolved completely in 41 (73%) patients and improved in the remaining 8 (14%). Similar results have been described with BV in patients with relapsed (41% of PN of any grade) and newly diagnosed systemic ALCL. Larger experiences with BV support PN and neutropenia as the most common adverse effects associated with this therapy. Like in younger patients, in elderly patients, PN (78%), fatigue (44%), and nausea (44%) are the most commonly observed AEs with a low incidence of grade 2 or 3 treatment-related anemia and neutropenia (2 patients each). Finally, in the retreatment setting, single-agent BV was associated to a toxicity profile similar in type and frequency to that described in the pivotal trials but with a higher incidence of PN (28% versus 11% for patients in the pivotal trial), mostly grade 1 or 2 in severity.

Finally, preliminary results showed that the association of BV with bleomycin included in the ABVD regimen resulted in significant incidence of pulmonary side effects with up to 44% of patients developing some grade of lung toxicity including 2 deaths.

Quality of life in patients treated with BV

Lymphoma patients have a high symptom burden which is associated with reduced overall health-related quality of life (HRQoL). Therefore, treatment objectives should be aimed to delay disease progression, optimize quality of response, and prolong OS coupled with maintaining HRQoL and minimizing treatment-related toxicity and discomfort.

In the 2 pivotal Phase II multicenter, open-label trials that evaluated the safety and efficacy of BV in patients with RRHL or systemic ALCL, results of HRQoL were evaluated in patients with long-term follow-up (median, 5 years) achieving overall objective response. Data were collected using a specifically designed, brief, 8-question survey that included patient-reported outcomes including physical, emotional, functional, and psychosocial data. These questionnaires were administered in paper format at the hospital. Overall, 38 patients participated in the survey and 66% of them completed it. Statistically significant symptom relief...
including improvement in patients’ energy level, in the ability to perform daily tasks, and in the capacity to perform physical activities was observed at post-baseline assessments, including in the subgroup of patients undergoing ASCT after treatment with BV. The sustained improvement in HRQoL reported was indicative of good tolerability, however caution is required, because the method has not been validated and the sample size is small.

In the Phase III, AETHERA trial, HRQoL was evaluated using the European Quality of Life-5 Dimensions scale, with patients completing this questionnaire at several time points: at the beginning of each cycle, at the end of treatment, and every 3 months during follow-up. Results showed a modest negative impact of BV on HRQoL when compared to those reported by patients in the placebo arm, but differences did not reach statistical significance.

Conclusion

The introduction of BV to the treatment landscape of HL and ALCL has proven to be transformative and will allow expanding the therapeutic arsenal and improving the prognosis in these patients. Several aspects of BV-associated results are striking. First, it has a high level of single-agent antitumor activity. Second, the safety profile is outstanding, with PN being the most commonly reported AE, but it appears to be manageable with symptomatic treatment and dose modifications and did not result in an increase in discontinuation of study treatments or deaths. In fact, BV has been combined with currently used conventional chemotherapy regimens, and we already have data that BV can be safely added to several backbone regimens to increase efficacy and prolong durability of the response in these patients and provide them new therapeutic alternatives. Current trials are evaluating different combinations of BV with a variety of agents. Results of these studies may change the current standards of care for patients with HL. However, mature data needed for final conclusions are still pending.

The high response rate and favorable toxicity profile of BV observed in the relapsed and refractory setting has allowed the rapid move of BV to the first-line therapy trials. In elderly patients with HL, BV alone or in combination may be a front-line option based on high response rate and favorable toxicity profile. Likewise, preliminary data suggest that early consolidation with BV after ASCT improves PFS, so it seems to be a reasonable option in patients with HL who are at high risk of progression after SCT. In patients with HL, the administration of BV-based therapies in earlier phases of the disease could reduce the proportion of refractory HL and diminish the number of patients undergoing high-dose therapy and ASCT. In our opinion, this is a crucial point to reduce long-term toxicity of chemotherapy in these patients.

HL and ALCL patients had suffered years of scarce therapeutic progress. BV is the first monoclonal antibody approved for treating these diseases, ending a decades-long wait for a targeted approach. Amid all the exciting possibilities opened up with the incorporation of this new drug, we also need much caution to detect potential long-term effects of BV therapy, and as the drug becomes more prominent in the treatment of earlier stages of the disease, collection of such data ideally through randomized trials to shed light on this aspect will become increasingly important.

Disclosure

The authors report no conflicts of interest in this work.

References


